|
1
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zakowski MF, Ladanyi M and Kris MG;
Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome
Group, : EGFR mutations in small-cell lung cancers in patients who
have never smoked. N Engl J Med. 355:213–215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yano S, Wang W, Li Q, Matsumoto K,
Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka
Y, et al: Hepatocyte growth factor induces gefitinib resistance of
lung adenocarcinoma with epidermal growth factor
receptor-activating mutations. Cancer Res. 68:9479–9487. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miller VA, Hirsh V, Cadranel J, Chen YM,
Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, et al: Afatinib
versus placebo for patients with advanced, metastatic
non-small-cell lung cancer after failure of erlotinib, gefitinib,
or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase
2b/3 randomised trial. Lancet Oncol. 13:528–538. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jänne PA, Yang JC, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J
Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sequist LV, von Pawel J, Garmey EG,
Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE,
Orlov S, et al: Randomized phase II study of erlotinib plus
tivantinib versus erlotinib plus placebo in previously treated
non-small-cell lung cancer. J Clin Oncol. 29:3307–3315. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Spigel DR, Ervin TJ, Ramlau RA, Daniel DB,
Blumenschein JH Jr, Goldschmidt GR Jr, Krzakowski MJ, Robinet G,
Godbert B, Barlesi F, et al: Randomized phase II trial of
Onartuzumab in combination with erlotinib in patients with advanced
non-small-cell lung cancer. J Clin Oncol. 31:4105–4114. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Robinson KW and Sandler AB: The role of
MET receptor tyrosine kinase in non-small cell lung cancer and
clinical development of targeted anti-MET agents. Oncologist.
18:115–122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nishino K, Imamura F, Morita S, Mori M,
Komuta K, Kijima T, Namba Y, Kumagai T, Yamamoto S, Tachibana I, et
al: A retrospective analysis of 335 Japanese lung cancer patients
who responded to initial gefitinib treatment. Lung Cancer.
82:299–304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Watanabe S, Tanaka J, Ota T, Kondo R,
Tanaka H, Kagamu H, Ichikawa K, Koshio J, Baba J, Miyabayashi T, et
al: Clinical responses to EGFR-tyrosine kinase inhibitor
retreatment in non-small cell lung cancer patients who benefited
from prior effective gefitinib therapy: A retrospective analysis.
BMC Cancer. 11:12011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oh IJ, Ban HJ, Kim KS and Kim YC:
Retreatment of gefitinib in patients with non-small-cell lung
cancer who previously controlled to gefitinib: A single-arm,
open-label, phase II study. Lung Cancer. 77:121–127. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yokouchi H, Yamazaki K, Kinoshita I,
Konishi J, Asahina H, Sukoh N, Harada M, Akie K, Ogura S, Ishida T,
et al: Clinical benefit of readministration of gefitinib for
initial gefitinib-responders with non-small cell lung cancer. BMC
Cancer. 7:512007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wong AS, Soong R, Seah SB, Lim SW, Chuah
KL, Nga ME, Chin TM and Soo RA: Evidence for disease control with
erlotinib after gefitinib failure in typical gefitinib-sensitive
Asian patients with non-small cell lung cancer. J Thorac Oncol.
3:400–404. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wong MK, Lo AI, Lam B, Lam WK, Ip MS and
Ho JC: Erlotinib as salvage treatment after failure to first-line
gefitinib in non-small cell lung cancer. Cancer Chemother
Pharmacol. 65:1023–1028. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vasile E, Tibaldi C, Chella A and Falcone
A: Erlotinib after failure of gefitinib in patients with advanced
non-small cell lung cancer previously responding to gefitinib. J
Thorac Oncol. 3:912–914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Costa DB, Nguyen KS, Cho BC, Sequist LV,
Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, et al:
Effects of erlotinib in EGFR mutated non-small cell lung cancers
with resistance to gefitinib. Clin Cancer Res. 14:7060–7067. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cho BC, Im CK, Park MS, Kim SK, Chang J,
Park JP, Choi HJ, Kim YJ, Shin SJ, Sohn JH, et al: Phase II study
of erlotinib in advanced non-small-cell lung cancer after failure
of gefitinib. J Clin Oncol. 25:2528–2533. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee DH, Kim SW, Suh C, Yoon DH, Yi EJ and
Lee JS: Phase II study of erlotinib as a salvage treatment for
non-small-cell lung cancer patients after failure of gefitinib
treatment. Ann Oncol. 19:2039–2042. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kuiper JL, Heideman DA, Thunnissen E, Paul
MA, van Wijk AW, Postmus PE and Smit EF: Incidence of T790M
mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Lung Cancer. 85:19–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hata A, Katakami N, Yoshioka H, Kaji R,
Masago K, Fujita S, Imai Y, Nishiyama A, Ishida T, Nishimura Y and
Yatabe Y: Spatiotemporal T790M heterogeneity in individual patients
with EGFR-mutant non-small-cell lung cancer after acquired
resistance to EGFR-TKI. J Thorac Oncol. 10:1553–1559. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakamura T, Sueoka-Aragane N, Iwanaga K,
Sato A, Komiya K, Abe T, Ureshino N, Hayashi S, Hosomi T, Hirai M,
et al: A noninvasive system for monitoring resistance to epidermal
growth factor receptor tyrosine kinase inhibitors with plasma DNA.
J Thorac Oncol. 6:1639–1648. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Umeguchi H, Sueoka-Aragane N, Kobayashi N,
Nakamura T, Sato A, Takeda Y, Hayashi S, Sueoka E and Kimura S:
Usefulness of plasma HGF level for monitoring acquired resistance
to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Oncol Rep. 33:391–396. 2015.PubMed/NCBI
|
|
30
|
Sueoka-Aragane N, Katakami N, Satouchi M,
Yokota S, Aoe K, Iwanaga K, Otsuka K, Morita S, Kimura S, Negoro S,
et al: Monitoring EGFR T790M with plasma DNA from lung cancer
patients in a prospective observational study. Cancer Sci.
107:162–167. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L;
International Association for the Study of Lung Cancer
International Staging Committee, : Participating Institutions: The
IASLC lung cancer staging project: Proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakamura T, Sueoka-Aragane N, Iwanaga K,
Sato A, Komiya K, Kobayashi N, Hayashi S, Hosomi T, Hirai M, Sueoka
E and Kimura S: Application of a highly sensitive detection system
for epidermal growth factor receptor mutations in plasma DNA. J
Thorac Oncol. 7:1369–1381. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bach PB, Silvestri GA, Hanger M and Jett
JR: American College of Chest Physicians: Screening for lung
cancer: ACCP evidence-based clinical practice guidelines (2nd
edition). Chest. 132 Suppl 3:69S–77S. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Suda K, Murakami I, Katayama T, Tomizawa
K, Osada H, Sekido Y, Maehara Y, Yatabe Y and Mitsudomi T:
Reciprocal and complementary role of MET amplification and EGFR
T790M mutation in acquired resistance to kinase inhibitors in lung
cancer. Clin Cancer Res. 16:5489–5498. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Marusyk A and Polyak K: Tumor
heterogeneity: Causes and consequences. Biochim Biophys Acta.
1805:105–117. 2010.PubMed/NCBI
|
|
36
|
Gerlinger M, Rowan AJ, Horswell S, Larkin
J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A,
Tarpey P, et al: Intratumor heterogeneity and branched evolution
revealed by multiregion sequencing. N Engl J Med. 366:883–892.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Swanton C: Intratumor heterogeneity:
Evolution through space and time. Cancer Res. 72:4875–4882. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yano S, Yamada T, Takeuchi S, Tachibana K,
Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, et
al: Hepatocyte growth factor expression in EGFR mutant lung cancer
with intrinsic and acquired resistance to tyrosine kinase
inhibitors in a Japanese cohort. J Thorac Oncol. 6:2011–2017. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chang JW, Chou CL, Huang SF, Wang HM,
Hsieh JJ, Hsu T and Cheung YC: Erlotinib response of EGFR-mutant
gefitinib-resistant non-small-cell lung cancer. Lung Cancer.
58:414–417. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gridelli C, Maione P, Galetta D,
Colantuoni G, Del Gaizo F, Ferrara C, Guerriero C, Nicolella D and
Rossi A: Three cases of long-lasting tumor control with erlotinib
after progression with gefitinib in advanced non-small cell lung
cancer. J Thorac Oncol. 2:758–761. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sundaresan TK, Sequist LV, Heymach JV,
Riely GJ, Jänne PA, Koch WH, Sullivan JP, Fox DB, Maher R,
Muzikansky A, et al: Detection of T790M, the acquired resistance
EGFR mutation, by tumor biopsy versus noninvasive blood-based
analyses. Clin cancer res. 22:1103–1110. 2016. View Article : Google Scholar : PubMed/NCBI
|
